It has previously been shown that anakinra, the recombinant form of IL-1 receptor antagonist, reduces inflammation in CF by down-regulating the pathogenic activity of the NLRP3 inflammasome [10] and reducing the hypoxia-driven inflammation [19]. Here, NLRP3 is linked to cystic fibrosis.